desloratadine + placebo + cetirizine

ApprovedCompleted

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Urticaria

Conditions

Urticaria

Trial Timeline

May 6, 2004 → May 24, 2005

NCT ID

NCT00751218

About desloratadine + placebo + cetirizine

desloratadine + placebo + cetirizine is a approved stage product being developed by Organon for Urticaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00751218. Target conditions include Urticaria.

What happened to similar drugs?

7 of 20 similar drugs in Urticaria were approved

Approved (7) Terminated (3) Active (11)

✅OMALIZUMABNovartisApproved

✅Levocetirizine + Levocetirizine plus HydroxyzineUCBApproved

✅Levocetirizine + DesloratadineUCBApproved

✅Desloratadine + Cetirizine + placeboOrganonApproved

✅5-mg Desloratadine + 10-mg Desloratadine + 20-mg DesloratadineOrganonApproved

✅desloratadine + desloratadineOrganonApproved

✅DesloratadineOrganonApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00751218	Approved	Completed	May 6, 2004	May 24, 2005	Urticaria

Competing Products

20 competing products in Urticaria

See all competitors

Product	Company	Stage	Hype Score
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
CT-P39 + EU-approved Xolair	Celltrion	Phase 3	40
Omalizumab	Celltrion	Pre-clinical	33
LY3454738 + Placebo	Eli Lilly	Phase 2	27
AZD1981 + Placebo	AstraZeneca	Phase 2	35
Benralizumab + Placebo and Benralizumab	AstraZeneca	Phase 2	27
LOU064	Novartis	Phase 3	40
Ligelizumab + Omalizumab	Novartis	Phase 3	40
Ligelizumab + Placebo	Novartis	Phase 1	21
Omalizumab	Novartis	Phase 2	35
canakinumab	Novartis	Phase 2	35
LOU064	Novartis	Phase 2	35
Omalizumab (Xolair) + Placebo	Novartis	Phase 2/3	38
LOU064 Arm 1 + LOU064 Arm 2 + LOU064 Arm 3 + LOU064 Arm 4 + LOU064 Arm 5 + LOU064 Arm 6 + Placebo arm	Novartis	Phase 2	35
LOU064 (blinded) + placebo	Novartis	Phase 3	47
Remibrutinib + Remibrutinib matching placebo + Dupilumab + Placebo solution for injection	Novartis	Phase 3	47